PD-1 / PD-L1 Checkpoint Inhibitor Immunotherapy

PD-1 and PD-L1 checkpoint inhibitors (Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab) represent a paradigm shift in cancer treatment. By blocking the PD-1/PD-L1 pathway, these agents remove the "brakes" that cancer cells place on the immune system, allowing T-cells to recognise and destroy tumours. At Dr. Joshi's Cancer Centre, checkpoint inhibitors are used in eligible patients with non-small cell lung cancer (PD-L1 ≥50%), melanoma, urothelial carcinoma, gastric cancer, Hodgkin lymphoma and others. Biomarker testing (PD-L1 IHC, TMB, MSI-H/dMMR status) is arranged before initiation. Immune-related adverse events (pneumonitis, colitis, hepatitis, endocrinopathies) are monitored with every cycle and managed with corticosteroids if required.

📋 Treatment Overview

📅 Schedule a Consultation

Talk to Dr. Joshi about whether this treatment is right for you. OPD: Mon–Thu, 10 AM – 1 PM.